Cargando…
Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701460/ https://www.ncbi.nlm.nih.gov/pubmed/31456692 http://dx.doi.org/10.3389/fphys.2019.00992 |
_version_ | 1783445064588984320 |
---|---|
author | Hwang, Hyun Seok Baldo, Marcelo P. Rodriguez, Jose Pindado Faggioni, Michela Knollmann, Bjorn C. |
author_facet | Hwang, Hyun Seok Baldo, Marcelo P. Rodriguez, Jose Pindado Faggioni, Michela Knollmann, Bjorn C. |
author_sort | Hwang, Hyun Seok |
collection | PubMed |
description | BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC suppresses spontaneous Ca(2+) waves in Casq2-knockout (Casq2(−/−)) cardiomyocytes, a CPVT model. However, a report failed to find FLEC efficacy against Ca(2+) waves in another CPVT model, RyR2-R4496C heterozygous mice (RyR2(R4496C+/−)), raising the possibility that FLEC efficacy may be mutation dependent. OBJECTIVE: To address this controversy, we compared FLEC in Casq2(−/−) and RyR2(R4496C+/−) cardiomyocytes and mice under identical conditions. METHODS: After 30 min exposure to FLEC (6 μM) or vehicle (VEH), spontaneous Ca(2+) waves were quantified during a 40 s pause after 1 Hz pacing train in the presence of isoproterenol (ISO, 1 μM). FLEC efficacy was also tested in vivo using a low dose (LOW: 3 mg/kg ISO + 60 mg/kg caffeine) or a high dose catecholamine challenge (HIGH: 3 mg/kg ISO + 120 mg/kg caffeine). RESULTS: In cardiomyocytes, FLEC efficacy was dependent on extracellular [Ca(2+)]. At 2 mM [Ca(2+)], only Casq2(−/−) myocytes exhibited Ca(2+) waves, which were strongly suppressed by FLEC. At 3 mM [Ca(2+)] both groups exhibited Ca(2+) waves that were suppressed by FLEC. At 4 mM [Ca(2+)], FLEC no longer suppressed Ca(2+) waves in both groups. Analogous to the results in myocytes, RyR2(R4496C+/−) mice (n = 12) had significantly lower arrhythmia scores than Casq2(−/−) mice (n = 9), but the pattern of FLEC efficacy was similar in both groups (i.e., reduced FLEC efficacy after HIGH dose catecholamine challenge). CONCLUSION: FLEC inhibits Ca(2+) waves in RyR2(R4496C+/−) cardiomyocytes, indicating that RyR2 channel block by FLEC is not mutation-specific. However, FLEC efficacy is reduced by Ca(2+) overload in vitro or by high dose catecholamine challenge in vivo, which could explain conflicting literature reports. |
format | Online Article Text |
id | pubmed-6701460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67014602019-08-27 Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload Hwang, Hyun Seok Baldo, Marcelo P. Rodriguez, Jose Pindado Faggioni, Michela Knollmann, Bjorn C. Front Physiol Physiology BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC suppresses spontaneous Ca(2+) waves in Casq2-knockout (Casq2(−/−)) cardiomyocytes, a CPVT model. However, a report failed to find FLEC efficacy against Ca(2+) waves in another CPVT model, RyR2-R4496C heterozygous mice (RyR2(R4496C+/−)), raising the possibility that FLEC efficacy may be mutation dependent. OBJECTIVE: To address this controversy, we compared FLEC in Casq2(−/−) and RyR2(R4496C+/−) cardiomyocytes and mice under identical conditions. METHODS: After 30 min exposure to FLEC (6 μM) or vehicle (VEH), spontaneous Ca(2+) waves were quantified during a 40 s pause after 1 Hz pacing train in the presence of isoproterenol (ISO, 1 μM). FLEC efficacy was also tested in vivo using a low dose (LOW: 3 mg/kg ISO + 60 mg/kg caffeine) or a high dose catecholamine challenge (HIGH: 3 mg/kg ISO + 120 mg/kg caffeine). RESULTS: In cardiomyocytes, FLEC efficacy was dependent on extracellular [Ca(2+)]. At 2 mM [Ca(2+)], only Casq2(−/−) myocytes exhibited Ca(2+) waves, which were strongly suppressed by FLEC. At 3 mM [Ca(2+)] both groups exhibited Ca(2+) waves that were suppressed by FLEC. At 4 mM [Ca(2+)], FLEC no longer suppressed Ca(2+) waves in both groups. Analogous to the results in myocytes, RyR2(R4496C+/−) mice (n = 12) had significantly lower arrhythmia scores than Casq2(−/−) mice (n = 9), but the pattern of FLEC efficacy was similar in both groups (i.e., reduced FLEC efficacy after HIGH dose catecholamine challenge). CONCLUSION: FLEC inhibits Ca(2+) waves in RyR2(R4496C+/−) cardiomyocytes, indicating that RyR2 channel block by FLEC is not mutation-specific. However, FLEC efficacy is reduced by Ca(2+) overload in vitro or by high dose catecholamine challenge in vivo, which could explain conflicting literature reports. Frontiers Media S.A. 2019-08-13 /pmc/articles/PMC6701460/ /pubmed/31456692 http://dx.doi.org/10.3389/fphys.2019.00992 Text en Copyright © 2019 Hwang, Baldo, Rodriguez, Faggioni and Knollmann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Hwang, Hyun Seok Baldo, Marcelo P. Rodriguez, Jose Pindado Faggioni, Michela Knollmann, Bjorn C. Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
title | Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
title_full | Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
title_fullStr | Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
title_full_unstemmed | Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
title_short | Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload |
title_sort | efficacy of flecainide in catecholaminergic polymorphic ventricular tachycardia is mutation-independent but reduced by calcium overload |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701460/ https://www.ncbi.nlm.nih.gov/pubmed/31456692 http://dx.doi.org/10.3389/fphys.2019.00992 |
work_keys_str_mv | AT hwanghyunseok efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload AT baldomarcelop efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload AT rodriguezjosepindado efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload AT faggionimichela efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload AT knollmannbjornc efficacyofflecainideincatecholaminergicpolymorphicventriculartachycardiaismutationindependentbutreducedbycalciumoverload |